Compare AMTB & VOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AMTB | VOR |
|---|---|---|
| Founded | 1979 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.4B |
| IPO Year | 2018 | 2021 |
| Metric | AMTB | VOR |
|---|---|---|
| Price | $28.58 | $23.82 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 3 | 10 |
| Target Price | $23.67 | ★ $45.33 |
| AVG Volume (30 Days) | 395.7K | ★ 773.6K |
| Earning Date | 04-23-2026 | 05-11-2026 |
| Dividend Yield | ★ 1.57% | N/A |
| EPS Growth | ★ 386.36 | N/A |
| EPS | ★ 0.97 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $8.29 | N/A |
| Revenue Next Year | $7.67 | N/A |
| P/E Ratio | $29.66 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $15.62 | $1.90 |
| 52 Week High | $30.60 | $49.95 |
| Indicator | AMTB | VOR |
|---|---|---|
| Relative Strength Index (RSI) | 54.09 | 60.10 |
| Support Level | $21.68 | $21.75 |
| Resistance Level | $30.60 | $24.34 |
| Average True Range (ATR) | 0.64 | 1.13 |
| MACD | -0.23 | -0.18 |
| Stochastic Oscillator | 29.74 | 54.84 |
Amerant Bancorp Inc is a bank holding company. Through its bank, it provides individuals and businesses deposit, credit, investment, wealth management, and fiduciary services, both in the United States and to select international customers. The bank also provides banking services through traditional channels, such as banking centers and ATMs, as well as via secure websites, mobile devices and telephones.
Vor Biopharma Inc is a clinical-stage biopharmaceutical company focused on developing novel therapies for the treatment of autoimmune diseases. Its program, telitacicept, is a potential first- and best-in-class dual BAFF/APRIL inhibitor designed to suppress the signaling pathways that drive the maturation, proliferation, and survival of harmful B cells, including self-reactive B cells, thereby reducing autoantibody production and preventing downstream tissue damage.